Form 8-K - Current report:
SEC Accession No. 0001193125-25-057823
Filing Date
2025-03-19
Accepted
2025-03-19 16:05:22
Documents
15
Period of Report
2025-03-19
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d901463d8k.htm   iXBRL 8-K 26296
2 EX-99.1 d901463dex991.htm EX-99.1 57140
6 GRAPHIC g901463g0318201719080.jpg GRAPHIC 4316
  Complete submission text file 0001193125-25-057823.txt   222158

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA scph-20250319.xsd EX-101.SCH 2881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE scph-20250319_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scph-20250319_pre.xml EX-101.PRE 11282
17 EXTRACTED XBRL INSTANCE DOCUMENT d901463d8k_htm.xml XML 3633
Mailing Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803
Business Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38293 | Film No.: 25752699
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)